龙沙（Lonza）和BioWa制药今天宣布，已与辉瑞（Pfizer）达成了一项合作协议，允许将POTELLIGENT®CHOK1SV细胞系用于辉瑞药物管线中数个专有抗体的研发。

POTELLIGENT®CHOK1SV是一株细胞系，用于生产重组抗体，该细胞系结合了BioWa制药的工程化糖基化POTELLIGENT技术及龙沙先进的GS基因表达系统的优势。GS系统包括了龙沙首屈一指的宿主细胞系CHOK1SV。

 

BioWa, Lonza sign licensing agreement with Pfizer for Potelligent CHOK1SV Cell Line

01 August 2013
 

BioWa and Lonza have inked an agreement with Pfizer for the use of their Potelligent CHOK1SV Cell Line in the research and development of multiple proprietary antibodies in the drugmaker’s pipeline.

features combined capabilities of BioWa's engineered glycosylation Potelligent Technology with Lonza's GS Gene Expression System which includes host cell line, CHOK1SV. 

Lonza Custom Development Services licensing vp head Karen Fallen said that the GS System and the CHOK1SV Cell Line continue to be a gold standard for therapeutic antibody development. 

"We are proud to be able to support Pfizer with this technology for their ongoing development portfolio," Fallen added.

Antibodies produced by Potelligent CHOK1SV Cell Line exhibit enhanced antibody dependent cellular cytotoxicity (ADCC) and can exert potent cytotoxic effects even when their target antigen is low. 

In addition, the antibodies work in whole blood and retain all other desirable features of common antibodies.